Medicine field: preserve the prescription acne description
Obagi identifies these products as prescription tretinoin treatments for acne vulgaris. That stated use should remain part of the description even when a reader begins with a question about skin aging. We do not rewrite the range as a universally approved wrinkle treatment based on the publication’s broader subject. Source 1
The acne-versus-photoaging chapter explains why a study or label needs its exact preparation and indication. A claim about another tretinoin medicine cannot automatically be transferred here. The FDA’s cosmetic-claim guidance supplies category context, rather than a new approval or clinical-effectiveness finding for every preparation listed by Obagi. Source 3
Strength field: the number does not identify the vehicle
The official range lists creams at 0.025%, 0.05% and 0.1%, alongside a 0.05% gel. At the overlapping concentration, cream and gel are still different preparation descriptions. A note that records only 0.05% tretinoin has not specified which one is being discussed. Source 1
The prescription-label chapter separates those fields because they answer different questions. We have not tested either vehicle’s spread, absorption or feel. The naming difference is a reason to identify the product precisely, not a basis for claiming that one form is universally stronger, gentler or better for a particular complexion.
Ingredient field: fragrance-free does not resolve every concern
The manufacturer describes fragrance-free formulations. That can answer a narrow question about the product’s positioning, but it does not establish that the active medicine or its vehicle cannot cause irritation. A full product record and the person’s current circumstances remain relevant to the discussion. Source 1
The AAD describes retinoids as a family with important distinctions between retail and prescription products. Its background is not an endorsement of a particular Obagi strength for an individual. We do not advise an application schedule or an independent switch of preparation based on the concise manufacturer page. Source 2
Dispensing field: ask for the actual supplied quantity
A manufacturer range page is not a completed dispensing label. It does not identify the quantity, pharmacy or product information attached to a particular person’s fill in this review. Those details need to come from the responsible care and dispensing process, rather than an assumed generic tube.
The label reference helps organize such questions without authenticating packaging or calculating a dose. Likewise, the storage and travel chapter directs attention to product-specific instructions. We have not supplied a shelf life, storage temperature or handling rule for a medicine that has not actually been dispensed to the reader.
Payment field: the missing quote should remain explicit
We did not verify cash cost, insurance contribution, consultation charges, delivery fees or pharmacy stock for an individual order. A comparable quote should name the active, strength, vehicle and quantity. A price from Obagi’s retail retinol range cannot fill those prescription fields. Source 1
The subscription and supply-cost chapter separates an initial payment from repeated charges and clinical review. Here the public range does not establish a complete agreement, so no monthly figure is invented. Before comparing offers, clarify which organization handles the medication, which handles the payment and whether another assessment is needed for a refill.
Terms field: keep the seller and product category connected
Cosmetic-store return terms should not be assumed to govern a pharmacy-dispensed prescription. The actual seller and applicable rules need to be identified before payment. We did not test cancellation, shipment tracking, a return or customer-service response time for these medicines.
For a separate provider pathway, the Likeness Rx review describes its own offer. Its ingredients and payment conditions do not describe an Obagi prescription. A useful manual connects related reading while preserving those boundaries, so a familiar active ingredient does not make different care models or transactions appear interchangeable.
The reference conclusion is specific: Obagi lists prescription acne preparations with named strengths and vehicles. Individual suitability, the complete dispensing record and final cost remain open. Taking those precise questions to the appropriate professional is more useful than inferring a clinical winner from brand recognition or a percentage alone.
If a quote omits the vehicle or quantity, mark the omission before comparing the total with another seller. If a label question remains, ask the dispensing pharmacist rather than reconstructing instructions from a manufacturer image. These are ways to obtain the missing record; they do not select a medicine, authenticate a package or change a clinician’s directions.